Serge Goblet: The Visionary Empire of 159 Million Euros, from Commerce to Revolutionary Biotechnology
Serge Goblet
Serge Goblet is a significant investor with a substantial net assets, valued at €159,388,000. Its main areas of activity are holding and real estate (Tolefi), with a strong presence in Brussels. Its empire rests on three main pillars: wholesale and distribution, real estate investments and investments in biotechnology companies. These include, Celyad Oncology SA is at the top of the list.

Celyad Oncologylocated in Mont-Saint-Guibert, Belgium, is a company specialized biotechnology in innovative chimeric antigen receptor T cell (CAR T) therapies for cancer treatment. This company, listed on Euronext and NASDAQ focuses on revolutionary therapies for cancer patients.

Goblet's investments in Celyad Oncology are part of an advanced biotechnology research framework. Celyad has obtained FDA approval for a study of its cardiac regeneration treatment, C-Cure, for patients suffering from chronic heart disease. This stem cell-based therapy represents a major breakthrough and began clinical trials in Europe in 2013, with the first treatments carried out in June 2014.

Goblet's portfolio is also highly diverse, including assets in Belgium and abroad, such as the distribution of mobile heating products, charcoal and pallets in Francein Italy and Spain. In conclusion, its commitment to biotechnology, and in particular to companies such as Celyad, underlines its crucial role in medical advances and the development of new products. contemporary therapeutics. This enabled him to accumulate a fortune of over 150 million euros.